Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12538944 | 0.82 | CA1 (0.35) | POLBHDAC6HDAC1HDAC2CA14 | |
| SCHEMBL12616124 | 0.79 | HDAC6 (0.35) | POLBHDAC6HDAC1HDAC2CA14 | |
| SCHEMBL9178624 | 0.79 | HDAC6 (0.32) | POLBHDAC6HDAC1HDAC2CA1 | |
| SCHEMBL12261426 | 0.78 | HDAC6 (0.36) | POLBHDAC6HDAC1HDAC2CA14 | |
| SCHEMBL16440494 | 0.78 | HDAC6 (0.36) | POLBHDAC6HDAC1HDAC2CA14 | |
| SCHEMBL9177642 | 0.77 | HDAC6 (0.33) | POLBHDAC6HDAC1HDAC2 | |
| SCHEMBL27487008 | 0.77 | CA1 (0.36) | POLBHDAC6HDAC1HDAC2CA14 | |
| SCHEMBL9173643 | 0.77 | HDAC6 (0.33) | POLBHDAC6HDAC1HDAC2 | |
| SCHEMBL503445 | 0.76 | HDAC6 (0.35) | POLBHDAC6HDAC1HDAC2CA14 | |
| SCHEMBL5345861 | 0.76 | AAK1 (0.35) | POLBHDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| EP-3672976-A1 | BCL-2 INHIBITORS | Newave Pharmaceutical Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040573-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-10065950-B2 | Substituted thiazoles as HIV integrase inhibitors | JAPAN TOBACCO INC. (JP) | 2018-09-04 | — | — | US | disclosed |
| WO-2017182495-A1 | INDAZOLE DERIVATIVES THAT DOWN-REGULATE THE ESTROGEN RECEPTOR AND POSSESS ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |
| EP-3215496-A2 | PANTOTHENAMIDE ANALOGUES | Radboud Universitair Medisch Centrum (NL) | 2017-09-13 | — | — | EP | disclosed |
| EP-3193611-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-07-26 | — | — | EP | disclosed |
| WO-2011119759-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2274306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009114566-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-2018371-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007136703-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-5589476-A | TREATMENT OF NAUSEA, VOMITING AND GASTROINTESTINAL DISORDERS | SYNTHELABO (FR) | 1996-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | IMPA1, IMPDH1, TYMP | POLB 107/4885HDAC6 2601/4885HDAC1 271/4885 |
| US-10065950-B2 | Substituted thiazoles as HIV integrase inhibitors | TYMP, TYMS, IMPDH1 | POLB 129/4885HDAC6 1319/4885HDAC1 247/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | POLB 4003/4885HDAC6 3664/4885HDAC1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.